Drug Use Investigation for AVOLVE(BPH)

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study is designed to investigate the safety and efficacy of dutasteride capsules 0.5 mg collected from the required number of Japanese subjects with benign prostatic hyperplasia (BPH) in order to identify concerns or problems, if any, about the efficacy and safety of its use at post-marketing clinical settings.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Dutasteride

Criteria

Inclusion Criteria:

• Must be male subjects

• Use dutasteride capsules for the first time

Exclusion Criteria:

• Subjects who is hypersensitivity to dutasteride or 5α reductase inhibitor

• Subjects with severe hepatic function disorder

• Dutasteride capsules shall not be used to female or child